Becton, Dickinson and Company (NYSE:BDX) EVP Michael David Garrison Sells 1,610 Shares of Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the transaction, the executive vice president directly owned 12,095 shares in the company, valued at $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Michael David Garrison also recently made the following trade(s):

• On Wednesday, December 17th, Michael David Garrison sold 629 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $196.03, for a total transaction of $123,302.87.

Becton, Dickinson and Company Stock Down 0.6%

BDX stock opened at $207.16 on Friday. The firm’s 50-day moving average is $195.88 and its two-hundred day moving average is $189.31. The company has a market capitalization of $59.02 billion, a price-to-earnings ratio of 35.53, a price-to-earnings-growth ratio of 2.30 and a beta of 0.23. Becton, Dickinson and Company has a 52 week low of $162.29 and a 52 week high of $251.99. The company has a current ratio of 1.11, a quick ratio of 0.64 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 EPS for the quarter, topping the consensus estimate of $3.92 by $0.04. The firm had revenue of $5.89 billion for the quarter, compared to analysts’ expectations of $5.91 billion. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The firm’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.81 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. On average, analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, December 31st. Investors of record on Monday, December 8th were issued a dividend of $1.05 per share. The ex-dividend date of this dividend was Monday, December 8th. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 dividend on an annualized basis and a yield of 2.0%. Becton, Dickinson and Company’s dividend payout ratio is presently 72.04%.

Analysts Set New Price Targets

A number of analysts recently commented on BDX shares. Royal Bank Of Canada boosted their target price on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a “sector perform” rating in a report on Wednesday, December 17th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Piper Sandler reduced their price objective on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a research note on Friday, November 7th. Bank of America boosted their target price on Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research report on Monday, January 5th. Finally, Stifel Nicolaus increased their price target on Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Four analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Becton, Dickinson and Company currently has an average rating of “Hold” and a consensus price target of $207.64.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. SOA Wealth Advisors LLC. increased its holdings in shares of Becton, Dickinson and Company by 256.8% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 95 shares during the period. Activest Wealth Management grew its position in Becton, Dickinson and Company by 285.3% during the third quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 97 shares in the last quarter. Imprint Wealth LLC acquired a new position in Becton, Dickinson and Company in the 3rd quarter valued at approximately $25,000. Bell Investment Advisors Inc lifted its position in Becton, Dickinson and Company by 474.1% in the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 128 shares in the last quarter. Finally, Cornerstone Planning Group LLC lifted its position in Becton, Dickinson and Company by 463.3% in the 3rd quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 139 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.